Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. COLL
  6. >
  7. Earnings
stocks logo

COLL Earnings

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings

Earning Analysis

Welcome to our in-depth analysis of Collegium Pharmaceutical Inc(COLL) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Collegium Pharmaceutical Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
FY2025Q32025-11-06Pre-Market1.692.06+21.89189.12M209.36M+10.70+13.42+25.08
FY2025Q22025-08-07Pre-Market1.431.68+17.48180.88M188.00M+3.93+10.72+27.29
FY2025Q12025-05-08After Hours1.291.49+15.50173.08M177.76M+2.70+5.94+6.60
FY2024Q42025-02-27After Hours1.411.75+24.11179.68M181.95M+1.26+2.22+4.86
FY2024Q22024-08-08After Hours1.401.62+15.71144.56M145.28M+0.49+0.51+0.45
FY2024Q12024-05-09-1.361.32-2.94146.94M144.92M-1.37-0.53-10.72
FY2023Q42024-02-22-1.201.45+20.83147.54M149.75M+1.49+3.31+15.14
FY2023Q32023-11-07-1.111.21+9.01139.54M136.71M-2.03-1.90+13.98
Financial AI Agent
Financial AI Agent

COLL Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Collegium Pharmaceutical Inc reported performance for FY2025Q3, announced on 2025-11-06. The company achieved an EPS of 2.06, compared to analyst estimates of 1.69 by 21.89% . Revenue for the quarter reached 209.36M compared to expectations of 189.12M by 10.70% .
The stock price reacted with a 13.42% one-day change and a 25.08% five-day change following the earnings release. These movements reflect market reaction in Collegium Pharmaceutical Inc growth trajectory and strategic initiatives.

COLL Earnings Forecast

Looking ahead, Collegium Pharmaceutical Inc(COLL) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 207.07M and an EPS of 2.14.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 3.56%, while EPS estimates have been Revise Downward by -4.09%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 3.7% . These revisions correlate with a 23.77% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Collegium Pharmaceutical Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between COLL's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.56%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.09%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
up Image
+3.7%
In Past 3 Month
Stock Price
Go Up
up Image
+23.77%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:782.20M
--
EPS Estimate-Annual FY 2025:7.47
—
Stock Price47.43
AI Stock Picker
AI Stock Picker

COLL Revenue and EPS Performance: A Historical Perspective

Collegium Pharmaceutical Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-11-06,Pre-Market):
EPS: 2.06 (Actual) vs.1.69 (Estimate) (21.89%)
Revenue: 209.36M (Actual) vs. 189.12M (Estimate) (10.70%)
Price Reaction: 13.42%(1-Day), 25.08%(5-Day)
FY2025Q2 (2025-08-07,Pre-Market):
EPS: 1.68 (Actual) vs.1.43 (Estimate) (17.48%)
Revenue: 188.00M (Actual) vs. 180.88M (Estimate) (3.93%)
Price Reaction: 10.72%(1-Day), 27.29%(5-Day)
FY2025Q1 (2025-05-08,After Hours):
EPS: 1.49 (Actual) vs.1.29 (Estimate) (15.50%)
Revenue: 177.76M (Actual) vs. 173.08M (Estimate) (2.70%)
Price Reaction: 5.94%(1-Day), 6.60%(5-Day)
Earnings Reaction
The chart below shows how COLL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, COLL sees a -1.63% change in stock price 10 days leading up to the earnings, and a +7.31% change 10 days following the report. On the earnings day itself, the stock moves by +3.50%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 4.03% on the day following the earnings release and then changed by 8.09% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Intellectia AI SwingMax
Intellectia AI SwingMax

Transcript Summary

Collegium Pharmaceutical Inc (COLL) Q3 2025 Earnings Call Summary
Positive
2025-11-06
The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
Collegium Pharmaceutical Inc (COLL) Q2 2025 Earnings Call Summary
Positive
2025-08-07
The earnings call shows strong financial performance with record revenue growth and optimistic guidance, particularly for Jornay PM. The new $150 million share repurchase program and debt repayment plan further enhance investor confidence. Despite increased operating expenses, the company's strategic focus on expanding market reach and awareness, especially among adults, is promising. The Q&A session did not reveal significant risks, and analysts seemed satisfied with management's responses. Considering the company's small-cap status, the positive developments are likely to result in a stock price increase of 2% to 8% over the next two weeks.
Collegium Pharmaceutical Inc (COLL) Q1 2025 Earnings Call Summary
Neutral
2025-05-08
The earnings call presents a mixed outlook. While financial performance shows growth, the decline in GAAP net income and EPS, alongside high operating expenses, raises concerns. The positive shareholder return plan and acquisition strategy are offset by competitive pressures and economic uncertainties highlighted in the Q&A. The market cap suggests moderate volatility, but the lack of clear guidance on key strategic initiatives tempers expectations. Overall, the sentiment is neutral given the balanced positives and negatives.
Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings Call Summary
Neutral
2025-02-28
The earnings call presents a mixed picture: strong revenue growth and a robust share repurchase program are positives, but increased operational costs, economic pressures, and lackluster synergy realization pose challenges. The Q&A session highlights uncertainties about future synergies and market dynamics. Despite a solid financial performance, the lack of clear guidance on key issues tempers optimism. Considering the company's small-cap status, the stock price is likely to remain stable, with potential fluctuations balanced by both positive and negative factors.
Collegium Pharmaceutical Inc (COLL) Q4 2024 Earnings Call Summary
Neutral
2025-02-27
The earnings call shows positive financial performance with increased revenues and a robust share repurchase program. However, competitive pressures, increased operational costs, and unclear management responses in the Q&A create uncertainties. Despite strong revenue growth, the significant rise in operating expenses and competitive market pressures balance out the positives. The market cap suggests moderate sensitivity to these factors, resulting in a neutral stock price movement prediction.
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Summary
Positive
2024-11-08
The earnings call summary shows strong revenue growth across most product lines, a decrease in net leverage, and a substantial share repurchase program, all of which are positive indicators. Despite increased operating expenses and a decline in net income, the company has strong non-GAAP adjusted EPS growth and a favorable new loan. The Q&A session reveals confidence in product differentiation and growth potential, with no significant negative sentiment from analysts. Given these factors, along with the company's small-cap status, a positive stock price reaction is expected over the next two weeks.

People Also Watch

FAQ

arrow icon

What were the key highlights of COLL’s latest earnings report for FY2025Q3?

COLL reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 209.36M against an estimate of 189.12M, resulting in a 10.7% surprise. The EPS was 2.06, surpassing the expected 1.69 by 21.89% . The stock experienced a 13.42% price change on the earnings day and a 25.08% change over the next five days, reflecting market reactions to the results.
arrow icon

How did COLL’s stock price react after the FY2025Q3 earnings release?

Following COLL’s FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 13.42% on the day of the release. Over the subsequent five days, it saw a 25.08% change. Historically, COLL’s stock price tends to shift by an average of -1.63% in the 10 days leading up to earnings and +7.31% in the 10 days following, providing insight into potential market.
arrow icon

What are the revenue and EPS estimates for COLL for 2025/Q4?

For 2025/Q4, analysts estimate COLL’s annual revenue to reach 207.07M, while the EPS is projected at 2.14. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 3.56% and EPS estimates Revise Upward by 3.7% over the past three months, indicating analyst expectation in the company’s performance.
arrow icon

How does COLL’s stock price correlate with earnings forecast revisions?

The correlation between COLL’s stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 3.56%, while EPS estimates moved Revise Upward by 3.7% . This trend suggests that price dips could present buying opportunities for investors.
arrow icon

What should investors expect from COLL’s next earnings report?

Based on historical trends, COLL’s stock price typically moves by -1.63% in the 10 days before its earnings and +7.31% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 2.14 and revenue of 207.07M.
arrow icon

What is the sentiment in Collegium Pharmaceutical Inc (COLL) Q3 2025 Earnings Call Summary?

The company reported record high revenue and strong earnings, coupled with optimistic guidance and a raised financial outlook. Despite some uncertainties in strategic execution and M&A specifics, the market is likely to react positively due to robust financial performance, a significant share repurchase program, and strategic growth initiatives. Given the company's small-cap status, these factors are expected to drive a positive stock price movement in the short term.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free